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Abstract We report a 3-year follow-up of high-dose
ubiquinol supplementation in a case of familial multiple sys-
tem atrophy (MSA) with compound heterozygous nonsense
(R387X) and missense (V393A) mutations in COQ2. A high-
dose ubiquinol supplementation substantially increased total
coenzyme Q10 levels in cerebrospinal fluid as well as in plas-
ma. The patient was at the advanced stage of MSA, and the
various scores of clinical rating scales remained stable without
changes during the 3 years. The cerebral metabolic ratio of
oxygen measured by 15O2 PET, however, increased by ap-
proximately 30% after administration of ubiquinol, suggesting
that ubiquinol can improve mitochondrial oxidative metabo-
lism in the brain. It also suggests the therapeutic potential of
ubiquinol for patients with MSA with COQ2 mutations.
Further clinical trials of administration of high-dose ubiquinol
to MSA patients are warranted.
Keywords Multiple system atrophy .COQ2 . Coenzyme
Q10 . Ubiquinol
Introduction
Multiple system atrophy (MSA) is a progressive neurodegen-
erative disease clinically characterized by autonomic failure in
addition to various combinations of parkinsonism, cerebellar
ataxia, and pyramidal dysfunction [1]. Whole-genome se-
quence analysis in combination with linkage analysis has re-
vealed homozygous or compound heterozygous mutations in
COQ2 in two of the six multiplex Japanese families with
MSA [2]. COQ2 encodes an enzyme in the biosynthetic path-
way of coenzyme Q10 (CoQ10) [3]. Indeed, the total CoQ10
levels in frozen brain tissues and lymphoblastoid cell lines
from patients with MSA carrying homozygous (M128V-
V393A/M128V-V393A) and compound heterozygous muta-
tions (R387X/V393A) were substantially lower than those
from control subjects [2]. These observations suggest the ef-
ficacy of CoQ10 supplementation for patients with MSA, in
particular, for those with COQ2 mutations.
CoQ10 is a lipophilic molecule that functions as an essential
carrier for electron transport in the mitochondrial respiratory
chain and as an endogenous antioxidant [4]. Patients with
primary CoQ10 deficiency, a severer phenotype than MSA,
caused by genetic defects in genes involved in the CoQ10
biosynthetic pathway, have been reported to respond well to
CoQ10 supplementation [5–11]. Herein, we present the de-
tailed clinical features of a patient with familial MSA carrying
compound heterozygous COQ2 mutations (R387X/V393A)
[2] and report the outcome of a high-dose ubiquinol (reduced
form of CoQ10) supplementation to this patient.
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The patient, a 60-year-old male, is an affected member
of a previously described Japanese multiplex family
with MSA (II-4 in Family 12) [2]. He carried com-
pound heterozygous nonsense (R387X, c.1159C>T) and
missense (V393A, c.1178T>C) mutations in COQ2
(NM_015697.7) [2, 12].
The patient gradually noticed slurring of speech, un-
steadiness of gait, increased urinary frequency, and erec-
tile dysfunction at the age of 44. Examination at the age
of 45 revealed jerky pursuit of eye movements, gaze-
evoked nystagmus, and scanning speech. Lower limb
movements were uncoordinated when performing the
heel-knee-shin test. His gait was ataxic, and he was un-
able to perform tandem gait. He had urinary urgency,
frequent urination, and erectile dysfunction. He also had
frequent orthostatic symptoms attributable to hypoten-
sion. His cognition and visual acuity were normal.
Brain magnetic resonance imaging (MRI) showed the
hot cross bun sign in the pontine base and mild atrophy
of the pons and cerebellum. He was then diagnosed as
having Bfamilial MSA^ because his elder sister had a
similar presentation with dysarthria and unsteady gait
with the onset at the age of 50. She died at the age of
61. He started intermittent catheterization at the age of
47 and had frequent orthostatic symptoms once a week
at the age of 48. He became wheelchair-bound at the age
of 50 and subsequently became bed-ridden owing to his
severe orthostatic symptoms. At the age of 56, his
speech was unintelligible most of the time due to the
severe ataxic dysarthria. At the age of 58, endoscopic
gastrostomy and laryngotracheal separation were per-
formed owing to his recurrent aspiration pneumonia. At
the age of 59, his renal function gradually worsened (se-
rum creatinine level, 1.0–1.5 mg/dl).
Study Design
An open-label dose escalation trial for this patient with
familial MSA with compound heterozygous COQ2 muta-
tions (R387X/V393A) was designed to evaluate the safe-
ty and tolerability of high-dose ubiquinol, to assess phar-
macokinetics, and to obtain the clinical data including
the scores of clinical rating scales [Barthel Index [13],
Scale for the Assessment and Rating of Ataxia (SARA)
[14], International Cooperative Ataxia Rating Scale
(ICARS) [15], and Unified Multiple System Atrophy
Rating Scale (UMSARS) [16]]. Positron emission tomog-
raphy (PET) was carried out to measure the cerebral
blood flow (CBF) and the cerebral metabolic rate of ox-
y g en (CMRO2 ) . Th e p r o t o c o l o f t h i s s t u dy
(UMIN000010712) was reviewed and approved by the
institutional review board of the participating institutions.
Informed consent was obtained from the patient and his
legal representative prior to the initiation of this study, in
accordance with the Declaration of Helsinki. Ubiquinol
in the powder form (Kaneka QH ubiquinol) was provid-
ed by Kaneka Corporation (Tokyo, Japan) and was ad-
ministered via a gastrostomy tube.
After baseline assessment, supplementation was
started at 600 mg of ubiquinol/day (given once a day),
with the dosage increased to 840 mg/day at week 2 and
to 1200 mg/day at week 6. The 1200-mg/day dosage
was maintained until week 8. When no adverse events
were observed during this period, the patient resumed
taking 1200 mg of ubiquinol/day after an interval of
8 weeks and remained taking ubiquinol at this same
dose for over 3 years to date.
Biochemical Analysis
Peripheral blood was collected into heparinized tubes to
obtain plasma samples. BD Vacutainer CPT Cell
Preparation Tubes (BD, Franklin Lakes, NJ) with sodium
heparin were used for separation of peripheral blood
mononuclear cells (PBMCs). The total CoQ10 levels
(sum of ubiquinol and ubiquinone levels) in plasma,
PBMCs, and cerebrospinal fluid (CSF) were measured
by high-performance liquid chromatography (HPLC) with
electrochemical detection (ECD) [17] or with tandem-
mass spectrometry (LC-MS/MS). For measurement of
the total CoQ10 level in CSF by HPLC with ECD,
400 μl of CSF was mixed with 1600 μl of isopropanol.
An aliquot of 1500 μl was evaporated to dryness and
resolved in 120 μl of isopropanol and 30 μl of distilled
water. An aliquot of 80 μl of the supernatant was directly
injected onto the HPLC equipped with the separation col-
umn (SHISEIDO CQ-S: 150 mm × 2.0 mm I.D.) with the
mobile phase of 50 mM sodium perchlorate in methanol/
distilled water (95/5, v/v). Measurement of the total
CoQ10 level in additional CSF samples obtained after
12, 24, and 36 months of ubiquinol supplementation was
conducted as follows. Twenty microliters of CSF was di-
luted to 5 ml with phosphate-buffered saline and mixed
with 8 ml of diethyl ether and 10 μl of internal standard
solution (200 ng/ml of CoQ8 in isopropanol). After the
solution was vigorously mixed, the supernatant separated
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by centrifugation was evaporated to dryness and resolved
in 20 μl of isopropanol. Quantitation of CoQ10 was ac-
complished by LC-MS/MS using Nexera X2 and LCMS-
8060 (Shimadzu, Japan).
Measurement of the CBF and the CMRO2 by PET
PET studies were carried out with 15O-labeled tracers
(15O2, C
15O2, and C
15O). The C15O2 and
15O2 steady-
state methods were used to measure the CBF and
CMRO2, respectively [18, 19]. PET scanning was per-
formed during C15O2 (370 MBq/min) or
15O2
(740 MBq/min) gas inhalation after equilibrium had been
reached. C15O PET (1110 MBq/min) was performed to
measure cerebral blood volume (CBV) that was used for
correction of CMRO2 [19–21]. PET imaging was per-
formed using a PET scanner (Headtome/SET2400 W,
Shimadzu).
For quantitative analysis, brain PET images before and
after ubiquinol supplementation were intrasubjectively
coregistered and morphologically normalized to the brain
PET template using statistical parametric mapping 8 and
MATLAB version R2014a (MathWorks Inc., Natick, MA,
USA). The regions of interest (ROIs) were manually
placed on the cortical ribbon of the upper frontal, lower
frontal, Rolandic, lateral and medial parietal, temporal,
and occipital areas and on the striatum, thalamus,
cerebellar hemisphere, and cerebellar vermis on the mor-
phologically normalized CBF PET images obtained before
supplementation. These ROIs were automatically applied
to other PET images, and each ROI value was then com-
putationally calculated.
Results
Ubiquinol Supplementation and Clinical Outcome
The analysis of the total CoQ10 levels in plasma and PBMCs
revealed a significant increase after 2 weeks of ubiquinol sup-
plementation at 600 mg/day (Table 1). The total CoQ10 levels
in plasma and PBMCs remained similar for another 4 weeks at
840 mg/day, and a subsequent 2-week administration of
ubiquinol at 1200 mg/day led to substantial increases in the
total CoQ10 levels in the plasma and the PBMCs. The CoQ10
level in CSF increased from 0.22 to 3.79 ng/ml after 2 weeks
of 840 mg/day, and a similar level of 3.64 ng/ml was observed
after 2 weeks of 1200 mg/day. Eight weeks after the last sup-
plementation of ubiquinol, the total CoQ10 levels in plasma,
PBMCs, and CSF returned to baseline levels.
Since we did not observe any adverse events at 1200 mg/
day dosage and ubiquinol supplementation at 1200 mg/day
led to higher total CoQ10 levels in the plasma and the
PBMCs compared with those observed with 840 mg/day, we
Table 1 Biochemical analyses
Total CoQ10 (μg/ml) in plasma Total CoQ10/free cholesterol
in PBMCs (nM/mM)
Total CoQ10 in CSF (μg/ml)








Before supplementation 0.33 281 0.22 × 10−3
After 2 weeks of 600 mg/day 5.04 1493 Not tested
After 2 weeks of 840 mg/day 4.02 1344 3.79 × 10−3
After 4 weeks of 840 mg/day 4.43 1636 Not tested
After 2 weeks of 1200 mg/day 7.86 2047 3.64 × 10−3
After 8 weeks of discontinuation 0.48 467 0.25 × 10−3
After 6 months of 1200 mg/day 4.15 1894 Not tested
After 12 months of 1200 mg/day 7.62 1891 7.36 × 10−3a
After 24 months of 1200 mg/day 4.92 Not tested 9.14 × 10−3a
After 36 months of 1200 mg/day 4.78 Not tested 14.06 × 10−3a
Total CoQ10, ubiquinol + ubiquinone
aMeasured by LC-MS/MS
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decided to maintain the 1200-mg/day dosage. After supple-
mentation of 1200 mg/day was resumed, the CoQ10 levels in
plasma and PBMCs returned to levels similar to those observed
after the initial 2weeks of 1200mg/day andmaintained at similar
levels throughout the following period. The CoQ10 levels in CSF
were 7.36, 9.14, and 14.06 ng/ml after 12, 24, and 36 months of
1200 mg/day, respectively. Thus, the total CoQ10 levels in CSF
gradually increased after resuming ubiquinol supplementation at
1200 mg/day for the following period (Table 1).
The patient continued to take 1200mg of ubiquinol/day for
over 3 years (Fig. 1). During the entire course, we did not
observe any adverse events that were considered to be
associated with the ubiquinol supplementation throughout
the entire study period. After 36 months of supplementa-
tion, evaluation of scores of clinical rating scales (Barthel
index, SARA, ICARS, and UMSARS) showed no remark-
able changes (Table 2). The brain MRI findings also
remained unchanged for the 3 years (Fig. 2). It was nota-
ble that his serum creatinine level gradually declined over
36 months (from 1.45 to 0.95 mg/dl) (Fig. 1). His body
weight decreased in the first 16 weeks (48.5 to 41.0 kg),
but gradually increased over 36 months (41.0 to 46.0 kg)
















Fig. 1 Summary of clinical
course with ubiquinol
supplementation. After the
baseline assessment, the patient
was started on ubiquinol at
600 mg/day (given once a day),
with the dose increased to
840 mg/day at week 2 and to
1200 mg/day at week 6. The
1200-mg/day dose was
maintained until week 8. After an
interval of 8 weeks, the patient
resumed taking ubiquinol at
1200 mg/day. To date, he remains
taking ubiquinol at this same dose
for over 3 years. BW body weight,
sCre serum creatinine level













Before supplementation 0 40 50 34 47 49 5
After a 2-week supplementation at 600 mg/day 0 40 50 34 47 47 5
After a 4-week supplementation at 840 mg/day 0 40 50 34 47 51 5
After a 2-week supplementation at 1200 mg/day 0 39 50 34 47 49 5
After a 6-month supplementation at 1200 mg/day 0 39 51 34 47 50 5
After a 12-month supplementation at 1200 mg/day 0 39 51 34 47 51 5
After an 18-month supplementation at 1200 mg/day 0 40 52 34 47 51 5
After a 24-month supplementation at 1200 mg/day 0 40 51 34 47 50 5
After a 30-month supplementation at 1200 mg/day 0 40 50 34 47 49 5
After a 36-month supplementation at 1200 mg/day 0 40 50 34 47 49 5
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Measurement of the CBF and the CMRO2 by PET
Figures 3 and 4 show CBF and CMRO2 images, respec-
tively, and Table 3 summarizes the quantitative measure-
ments before and after 2 weeks of ubiquinol supplemen-
tation at 1200 mg/day. At the baseline, CBF decreased
and CMRO2 markedly decreased in the entire brain. For
example, the CBF and CMRO2 in the Rolandic area were
30.6 ml/100 ml/min [reference level [19], 44.6, 5.6 (mean,
standard deviation)] and 1.81 ml/100 ml/min [reference
level [19], 3.3, 0.5 (mean, standard deviation)], respective-
ly. After 2 weeks of ubiquinol supplementation at
1200 mg/day, CBF remained unchanged as compared with
the baseline level (Fig. 3 and Table 3). In contrast, the
CMRO2 markedly increased by approximately 30% in the
entire brain (Fig. 4 and Table 3), although it did not reach
normal levels. For example, the CMRO2 in the Rolandic
area increased from 1.81 to 2.15 ml/100 ml/min [reference
level, 3.3, 0.5 (mean, standard deviation) [19]].
Discussion
In the present single case study of a patient with familial MSA
carrying compound heterozygous mutations inCOQ2, admin-
istration of high-dose ubiquinol led to a substantial increase in
the total CoQ10 levels not only in the plasma and PBMC but
also in the CSF. Although previous reports have failed to show
the increase in total CSF CoQ10 level by ubiquinone or
ubiquinol supplementation, which was caused possibly due
to the insufficient dose (300mg/day) [25], this is the first study
showing that ubiquinol supplementation at 840 and 1200 mg/
day clearly elevated the total CSF CoQ10 level. CoQ10 has
been reported to be poorly absorbed, and its bioavailability
varies among formulations [26]. Previous dose escalation
studies (up to 3000 mg/day) using chewable tablets of ubiqui-
none in patients with Parkinson disease, amyotrophic lateral
sclerosis, and Huntington disease concordantly showed that
the total plasma CoQ10 levels reached the plateau levels of
approximately 7.0–7.5 μg/ml after multiple doses of
After 36 months of ubiquinol 1,200 mg/day
Baseline assessment
Fig. 2 Brain MR images of
patient. Upper images were
obtained at 60 years of age
(before supplementation of
ubiquinol), and lower images
were obtained at 63 years of age
(after 36 months of ubiquinol
1200 mg/day). T1-weighted sag-
ittal images (left) and T2-weightd
axial images at the middle regions
of the pontine base (right). They
show gross atrophy of the
infratentorial structures especially
in the pons, middle cerebellar pe-
duncle, and cerebellum
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2400 mg/day [22–24]. When assessing the bioavailability of
ubiquinol in this study, the trough concentrations of total
CoQ10 in plasma were 5.04 μg/ml for 600 mg/day, 4.02 μg/
ml for 840 mg/day, and 7.86 μg/ml for 1200 mg/day 2 weeks
after the daily intake of ubiquinol. Furthermore, another pre-
vious study using ubiquinol showed that mean total plasma
CoQ10 levels were 2.61 μg/ml for 90 mg/day, 3.66 μg/ml for
150 mg/day, and 6.53 μg/ml for 300 mg/day 2 weeks after a
daily intake of ubiquinol [27]. These observations indicate
that ubiquinol is better absorbed in the gastrointestinal tract
than ubiquinone, and we conclude that the ubiquinol dose of
1200 mg/day is sufficient for achieving a plateau of total
CoQ10 level in plasma.
Remarkably, CMRO2 increased without an increase in
CBF after administration of 1200 mg of ubiquinol, which
suggests that ubiquinol improved cerebral mitochondrial oxi-
dative metabolism. Despite the increase in the CMRO2, how-
ever, we did not detect any obvious neurological improve-
ments as determined by the rating scales, presumably owing
to the advanced stage of neurodegeneration. Notably, his se-
rum creatinine level gradually declined during the ubiquinol
supplementation over 36 months (from 1.45 to 0.95 mg/dl).
Because renal involvement has been frequently observed in
patients with primary CoQ10 deficiency caused by genetic
defects in CoQ10 biosynthesis [28–30], the renal dysfunction
in the patient was likely caused by CoQ10 deficiency and was
ameliorated by ubiquinol supplementation. He also showed
weight loss in the first 16 weeks of supplementation (48.5 to
41.0 kg). We extensively investigated the cause of his weight
loss. However, we did not find chronic infectious diseases,
malignancies, extremity edema, pleural effusion, or ascites
in this patient during the entire study period. He gradually
regained his body weight over 36 months (41.0 to 46.0 kg)
after increasing his daily calorie intake. Despite the body
weigh changes, his general health condition remained stable.
Conclusions
The current study suggests that high-dose ubiquinol supple-
mentation (up to 1200 mg/day) is tolerable and improves ce-
rebral mitochondrial oxidative metabolism, which may alter
mg/day 1,200          ubiquinol  of2 weeks AfterBaseline assessment
Fig. 3 CBF images before and after ubiquinol supplementation at 1200 mg/day
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the natural history of MSA progression especially when ap-
plied in the early phase of MSA in patients with genetic de-
fects in the CoQ10 biosynthetic pathway. Further clinical trials
including administration of ubiquinol to MSA patients
carrying heterozygous COQ2 mutations as well as to patients
without mutations in COQ2 are warranted. Prospective ran-
domized controlled trials will be undertaken to further extend
these initial promising observations.
Table 3 CBF and CMRO2 in
major brain areas before and after
ubiquinol supplementation
CBF (ml/100 ml/min) CMRO2 (ml/100 ml/min)
Region Before After Before After
Upper frontal 28.8 27.7 1.78 2.17
Lower frontal 29.7 29.8 1.72 2.23
Rolandic 30.6 29.7 1.81 2.15
Lateral parietal 30.8 29.9 2.03 2.52
Medial parietal 35.3 42.1 2.05 3.12
Temporal 31.5 30.3 2.11 2.65
Occipital 38.2 37.5 2.63 3.17
Striatum 30.4 29.7 1.92 2.56
Thalamus 35.3 44.5 2.08 3.20
Cerebellar hemisphere 24.3 24.3 1.44 1.89
Cerebellar vermis 23.7 22.4 1.33 1.58
After 2 weeks of obiquinol 1,200 mg/dayBaseline assessment
Fig. 4 CMRO2 images before and after ubiquinol supplementation at 1200 mg/day
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